Truist Securities Reiterates Buy Rating on Cytokinetics (CYTK)

Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $70.00 price target on Cytokinetics (NASDAQ: CYTK).

The analyst commented: "We attended CYTK’s investor and analyst day. CYTK appears invested in building a specialty cardiology franchise to address expansion oppies and additional indications. We believe that the company has a best-in-class CMI and expect approval with less onerous REMS in 2025. While we model adj peak sales of $3B each for CYTK and BMY in oHCM, company views symptomatic HCM potential market = $10B. We model ~$400M in adj peak sales for afi in nHCM. While we do not assign any credit to HFpEF for CK-586, we believe that competitor data in HFpEF reads through and could provide upside. Cat rich year ahead. Reit Buy."

For an analyst ratings summary and ratings history on Cytokinetics click here. For more ratings news on Cytokinetics click here.

Shares of Cytokinetics closed at $55.28 yesterday.

You May Also Be Interested In

• Robinhood Ventures Fund II opens at $22.50, IPO at $25
• Tencent Holdings (700:HK) (TCEHY) PT Lowered to HK$625 at Benchmark to Reflect Downward Earnings Revisions
• Axos Financial (AX) PT Raised to $120 at Benchmark